Iambic Therapeutics filed for a Nasdaq IPO after raising $461.8 million. The company reported $2.9 million collaboration revenue, a $48.4 million net loss and $427.3 million in cash, while its lead cancer programme remains in Phase 1/1b trials.
HEALTHCARE & FITNESS
Takeda Wins FDA Approval for First-of-Its-Kind Treatment for Rare Blood Cancer
The FDA has approved Takeda Pharmaceutical and Protagonist Therapeutics’ rusfertide for polycythemia vera, offering patients a less-invasive alternative to frequent bloodletting procedures used to control excessive red blood cell production.
Popular Reads
Category . Author
Story
Cardinal Health Expands Home Care With $360M Deal
The healthcare distributor is strengthening its at-home solutions business through the acquisitions of AdaptHealth's diabetes unit and Strive Medical.
Abbott Reports Two Cyber Incidents
The healthcare company says unauthorised access was detected in parts of its cancer diagnostics business and LabCentral portal, with no disruption to business operations.
MS Patients Avoid $33,000 Treatment Costs Under PBS Deal
The government has confirmed that major multiple sclerosis medicines will remain on the PBS, providing financial relief for thousands of Australians.
Eli Lilly to Buy AtaiBeckley in Up to $3.8 Billion Psychedelic Drug Deal
Eli Lilly’s up to $3.8 billion acquisition of AtaiBeckley strengthens its push into psychedelic therapies, adding the late-stage depression treatment BPL-003 to its growing neuroscience portfolio.
More healthcare & fitness News
01
Data Breach Exposes Patient Information Across GP Network
One of Australia's largest primary healthcare providers has confirmed a cyber incident affecting patient records at multiple clinics.
02
How ASX-listed pharma companies rebuild boards after leadership churn
Mayne Pharma’s board overhaul following its failed takeover highlights how ASX-listed pharmaceutical companies rebuild leadership, restore governance and reposition for long-term growth after major executive departures.
03
US Health Watchdog Reports Billions in Expected Savings
The agency expects US$5.56 billion in recoveries and savings, even as enforcement actions eased to a two-year low.